NASDAQ:INVA Innoviva - INVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.15 0.00 (0.00%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.11▼$11.2650-Day Range$10.73▼$13.0252-Week Range$10.64▼$20.71Volume470,680 shsAverage Volume986,828 shsMarket Capitalization$778.05 millionP/E Ratio5.39Dividend YieldN/APrice Target$15.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Innoviva MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside36.0% Upside$15.17 Price TargetShort InterestBearish13.20% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.84Based on 3 Articles This WeekInsider TradingAcquiring Shares$32,610 Bought Last QuarterProj. Earnings Growth-8.76%From $1.37 to $1.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector601st out of 1,009 stocksPharmaceutical Preparations Industry290th out of 494 stocks 3.0 Analyst's Opinion Consensus RatingInnoviva has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.17, Innoviva has a forecasted upside of 36.0% from its current price of $11.15.Amount of Analyst CoverageInnoviva has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.20% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 5.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 2.7 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Innoviva this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,610.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.89% of the stock of Innoviva is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Innoviva are expected to decrease by -8.76% in the coming year, from $1.37 to $1.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 5.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 5.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 141.86.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Innoviva (NASDAQ:INVA) StockInnoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.Read More Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Stock News HeadlinesMarch 13, 2023 | finance.yahoo.comInnoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted AntibioticFebruary 28, 2023 | finance.yahoo.comInnoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company ProgressMarch 31, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. February 28, 2023 | benzinga.comTheravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off StaffFebruary 13, 2023 | finance.yahoo.comShareholders in Innoviva (NASDAQ:INVA) are in the red if they invested a year agoDecember 28, 2022 | finance.yahoo.comInnoviva (INVA) Stock Moves -1.06%: What You Should KnowDecember 28, 2022 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently?December 19, 2022 | msn.comInnoviva Earnings Perspective: Return On Capital EmployedMarch 31, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. November 30, 2022 | finance.yahoo.comInnoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)November 11, 2022 | finance.yahoo.comInnoviva Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | finance.yahoo.comInnoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNovember 9, 2022 | finance.yahoo.comInnoviva (INVA) Q3 Earnings and Revenues Lag EstimatesOctober 19, 2022 | finance.yahoo.comInnoviva (INVA) Earnings Expected to Grow: Should You Buy?October 19, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022 - Yahoo FinanceOctober 19, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022October 14, 2022 | finance.yahoo.comLa Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022 - Yahoo FinanceOctober 14, 2022 | businesswire.comLa Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022 - Business WireOctober 14, 2022 | nasdaq.comValidea John Neff Strategy Daily Upgrade Report - 10/11/2022 - NasdaqOctober 12, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022 - Yahoo FinanceOctober 12, 2022 | finance.yahoo.comEntasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022October 9, 2022 | nasdaq.comInvestors who have held Innoviva (NASDAQ:INVA) over the last year have watched its earnings decline along with their investment - NasdaqSeptember 29, 2022 | finance.yahoo.comGate Neurosciences Publishes Data Highlighting Novel Mechanism of Lead Rapid-Acting Oral Antidepressant and Provides Business Update - Yahoo FinanceSeptember 27, 2022 | reuters.comINVA.OQ - Innoviva Inc | Stock Price & Latest News | ReutersSeptember 19, 2022 | seekingalpha.comInnoviva Stock? Not Yet. Short Puts? Definitely. (NASDAQ:INVA) - Seeking AlphaSeptember 8, 2022 | businesswire.comInnoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Business WireAugust 29, 2022 | globenewswire.comChronic Obstructive Pulmonary Disease Drug Market exhibiting a CAGR of 6.8 % and is expected to reach USD 1.6 Billion by 2029 - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Company Calendar Last Earnings10/27/2021Today3/31/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees5Year Founded1996Price Target and Rating Average Stock Price Forecast$15.17 High Stock Price Forecast$22.50 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+36.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio5.39 Forward P/E Ratio8.14 P/E GrowthN/ANet Income$213.92 million Net Margins64.56% Pretax Margin86.60% Return on Equity18.81% Return on Assets9.10% Debt Debt-to-Equity Ratio0.79 Current Ratio3.29 Quick Ratio2.87 Sales & Book Value Annual Sales$331.34 million Price / Sales2.35 Cash Flow$2.28 per share Price / Cash Flow4.90 Book Value$8.11 per share Price / Book1.37Miscellaneous Outstanding Shares69,780,000Free Float69,162,000Market Cap$778.05 million OptionableOptionable Beta0.56 Social Links Key ExecutivesPavel RaifeldChief Executive OfficerMarianne ZhenSecretary & Chief Accounting OfficerKey CompetitorsImmunoGenNASDAQ:IMGNIntercept PharmaceuticalsNASDAQ:ICPTMannKindNASDAQ:MNKDOPKO HealthNASDAQ:OPKEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsPavel RaifeldBought 3,000 shares on 3/10/2023Total: $32,610.00 ($10.87/share)Macquarie Group Ltd.Sold 26,650 shares on 2/21/2023Ownership: 0.090%Truist Financial CorpBought 33,726 shares on 2/17/2023Ownership: 0.048%DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am MainSold 258,843 shares on 2/16/2023Ownership: 0.312%State of WyomingSold 3,501 shares on 2/16/2023Ownership: 0.010%View All Insider TransactionsView All Institutional Transactions INVA Stock - Frequently Asked Questions Should I buy or sell Innoviva stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares. View INVA analyst ratings or view top-rated stocks. What is Innoviva's stock price forecast for 2023? 3 brokerages have issued 12-month price targets for Innoviva's shares. Their INVA share price forecasts range from $10.00 to $22.50. On average, they anticipate the company's stock price to reach $15.17 in the next twelve months. This suggests a possible upside of 36.0% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts. How have INVA shares performed in 2023? Innoviva's stock was trading at $13.25 at the beginning of the year. Since then, INVA shares have decreased by 15.8% and is now trading at $11.15. View the best growth stocks for 2023 here. Are investors shorting Innoviva? Innoviva saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,870,000 shares, an increase of 5.8% from the February 28th total of 8,380,000 shares. Based on an average daily trading volume, of 706,600 shares, the short-interest ratio is currently 12.6 days. Currently, 13.2% of the shares of the stock are short sold. View Innoviva's Short Interest. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of $0.43 by $0.47. The biotechnology company earned $97.86 million during the quarter. Innoviva had a net margin of 64.56% and a trailing twelve-month return on equity of 18.81%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows 100 ETF (CALF), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Janus Henderson Small Cap Growth Alpha ETF (JSML) and Distillate Small/Mid Cash Flow ETF (DSMC). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." Who are Innoviva's major shareholders? Innoviva's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.06%), Dimensional Fund Advisors LP (4.60%), Millennium Management LLC (3.06%), Systematic Financial Management LP (2.80%), Assenagon Asset Management S.A. (2.45%) and LSV Asset Management (2.35%). Insiders that own company stock include George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $11.15. How much money does Innoviva make? Innoviva (NASDAQ:INVA) has a market capitalization of $778.05 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.07 on an earnings per share basis. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690. This page (NASDAQ:INVA) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.